Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $5,460 | 8 | 99.7% |
| Food and Beverage | $16.40 | 1 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $5,460 | 8 | $0 (2020) |
| GlaxoSmithKline, LLC. | $16.40 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2020 | $1,056 | 3 | Merck Sharp & Dohme Corporation ($1,040) |
| 2019 | $1,560 | 2 | Merck Sharp & Dohme Corporation ($1,560) |
| 2018 | $1,560 | 2 | Merck Sharp & Dohme Corporation ($1,560) |
| 2017 | $1,300 | 2 | Merck Sharp & Dohme Corporation ($1,300) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/12/2020 | Merck Sharp & Dohme Corporation | GARDASIL (Biological) | Consulting Fee | Cash or cash equivalent | $780.00 | General |
| Category: VACCINE | ||||||
| 01/29/2020 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $16.40 | General |
| Category: IMMUNOLOGY | ||||||
| 01/06/2020 | Merck Sharp & Dohme Corporation | GARDASIL (Biological) | Consulting Fee | Cash or cash equivalent | $260.00 | General |
| Category: VACCINE | ||||||
| 06/07/2019 | Merck Sharp & Dohme Corporation | GARDASIL (Biological) | Consulting Fee | Cash or cash equivalent | $780.00 | General |
| Category: VACCINE | ||||||
| 02/27/2019 | Merck Sharp & Dohme Corporation | GARDASIL (Biological) | Consulting Fee | Cash or cash equivalent | $780.00 | General |
| Category: VACCINE | ||||||
| 12/05/2018 | Merck Sharp & Dohme Corporation | GARDASIL (Biological) | Consulting Fee | Cash or cash equivalent | $780.00 | General |
| Category: VACCINE | ||||||
| 07/31/2018 | Merck Sharp & Dohme Corporation | GARDASIL (Biological) | Consulting Fee | Cash or cash equivalent | $780.00 | General |
| Category: VACCINE | ||||||
| 08/16/2017 | Merck Sharp & Dohme Corporation | GARDASIL (Biological) | Consulting Fee | Cash or cash equivalent | $780.00 | General |
| Category: VACCINE | ||||||
| 01/30/2017 | Merck Sharp & Dohme Corporation | GARDASIL (Biological) | Consulting Fee | Cash or cash equivalent | $520.00 | General |
| Category: VACCINE | ||||||
About Dr. Andrew Eichenfield, M.D
Dr. Andrew Eichenfield, M.D is a Pediatric Rheumatology healthcare provider based in New Square, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1821061490.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Andrew Eichenfield, M.D has received a total of $5,476 in payments from pharmaceutical and medical device companies, with $1,056 received in 2020. These payments were reported across 9 transactions from 2 companies. The most common payment nature is "Consulting Fee" ($5,460).
Practice Information
- Specialty Pediatric Rheumatology
- Location New Square, NY
- Active Since 02/13/2006
- Last Updated 02/13/2025
- Taxonomy Code 2080P0216X
- Entity Type Individual
- NPI Number 1821061490
Products in Payments
- GARDASIL (Biological) $5,460
- BENLYSTA (Biological) $16.40
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.